TScan Therapeutics, Inc. (NASDAQ:TCRX) Given Average Rating of "Hold" by Analysts

Key Points

• Analyst consensus: "Hold" — Six analysts cover TCRX (1 sell, 2 hold, 3 buy) with a 12‑month average target of $6.00; recent notes include Wedbush raising its target to $5/outperform while others (Wall Street Zen, Weiss) issued sell views.
• High institutional ownership (82.83%) — Recent activity shows Goldman Sachs and JPMorgan adding to positions and new stakes by Marshall Wace, Qube Research and Jane Street.
• Weak fundamentals but recent beat — Shares trade near $1.06 with a $60.3M market cap, very negative margins and ROE, though the latest quarter beat EPS and revenue estimates; analysts forecast -1.12 EPS for the year.

TScan Therapeutics, Inc. (NASDAQ:TCRX - Get Free Report) has been assigned an average recommendation of "Hold" from the six analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $6.00.

A number of analysts have commented on the stock. Wedbush upped their target price on shares of TScan Therapeutics from $4.00 to $5.00 and gave the company an "outperform" rating in a report on Thursday, March 5th. Wall Street Zen downgraded shares of TScan Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 14th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of TScan Therapeutics in a research report on Thursday, January 22nd.

Institutional Investors Weigh In On TScan Therapeutics

A number of hedge funds have recently modified their holdings of TCRX. Goldman Sachs Group Inc. grew its position in shares of TScan Therapeutics by 6.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 170,349 shares of the company's stock valued at $235,000 after acquiring an additional 9,676 shares during the period. JPMorgan Chase & Co. grew its position in shares of TScan Therapeutics by 8.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 287,743 shares of the company's stock valued at $417,000 after acquiring an additional 22,642 shares during the period. Marshall Wace LLP bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $78,000. Qube Research & Technologies Ltd bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $99,000. Finally, Jane Street Group LLC bought a new stake in shares of TScan Therapeutics during the 2nd quarter valued at $309,000. Institutional investors own 82.83% of the company's stock.

TScan Therapeutics Stock Performance

TScan Therapeutics stock opened at $1.06 on Friday. The business has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.27. The company has a market cap of $60.31 million, a P/E ratio of -1.06 and a beta of 1.02. TScan Therapeutics has a 52-week low of $0.88 and a 52-week high of $2.57. The company has a quick ratio of 8.41, a current ratio of 8.41 and a debt-to-equity ratio of 0.26.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.09. The firm had revenue of $2.57 million during the quarter, compared to analyst estimates of $2.44 million. TScan Therapeutics had a negative net margin of 1,256.81% and a negative return on equity of 79.36%. Analysts predict that TScan Therapeutics will post -1.12 EPS for the current year.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan's approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company's pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.